Alliances
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan.
Ultragenyx CEO to present Keynote Address at the 2018 CDKL5 Forum hosted by the Loulou Foundation
Agreement demonstrates growing use of OncoDNA solutions across Europe
Oxurion NV announced today it is extending its partnership with Retina Global
Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary, Hemogenyx-Cell S.A. (“Hemogenyx-Cell”) has entered into a further collaboration agreement with Orgenesis, Inc (“Orgenesis”).
Voice solution provider now working with academic medical center to explore opportunities to improve patient care
Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary Immugenyx, LLC (“Immugenyx”) has entered into a collaboration agreement with Orgenesis, Inc.
Shares of Alexion Pharmaceuticals are up nearly 4 percent in premarket trading after the company announced it has teamed up with Dicerna Pharmaceuticals on the development of an RNAi therapeutic for the treatment of complement-mediated diseases.
Abdul Rahman bin Mohammed Al Owais, UAE Minister of Health and Prevention, signed a partnership agreement with Leif Johansson, Chairman of leading global pharmaceutical company AstraZeneca, as part of its strategy to enhance the outcomes of national indicators in the field of respiratory diseases and cancer, to achieve the objectives of the National Agenda 2021.
French company Innate Pharma and UK-based AstraZeneca have had a research collaboration deal in place since 2015. The two companies announced a new multi-term deal to build on that collaboration.
PRESS RELEASES